{"id":"al-oh-3","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL3961932","moleculeType":"Small molecule","molecularWeight":"423.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aluminum hydroxide is a widely used vaccine adjuvant that works by creating a depot effect at the injection site, slowing antigen release and enhancing uptake by antigen-presenting cells. It activates the NLRP3 inflammasome and promotes a Th2-biased immune response, increasing antibody production and cellular immunity against the vaccine antigen. This mechanism makes it particularly effective in enhancing humoral immune responses in vaccine formulations.","oneSentence":"Aluminum hydroxide acts as an adjuvant that enhances immune response by promoting antigen presentation and activating innate immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:26.040Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Aluminium_hydroxide","title":"Aluminium hydroxide","extract":"Aluminium hydroxide, Al(OH)3, is found as the mineral gibbsite and its three much rarer polymorphs: bayerite, doyleite, and nordstrandite. Aluminium hydroxide is amphoteric, i.e., it has both basic and acidic properties. Closely related are aluminium oxide hydroxide, AlO(OH), and aluminium oxide or alumina, the latter of which is also amphoteric. These compounds together are the major components of the aluminium ore bauxite. Aluminium hydroxide also forms a gelatinous precipitate in water."},"indications":{"approved":[{"name":"Vaccine adjuvant in phase 3 vaccine development by Janssen Vaccines & Prevention B.V."}]},"trialDetails":[{"nctId":"NCT05901636","phase":"PHASE1, PHASE2","title":"A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2023-05-17","conditions":"Influenza Prevention","enrollment":170},{"nctId":"NCT03284710","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-19","conditions":"HIV Infections","enrollment":132},{"nctId":"NCT05104489","phase":"PHASE1, PHASE2","title":"Dose-finding Study for AdimrSC-2f Vaccine","status":"COMPLETED","sponsor":"Adimmune Corporation","startDate":"2022-01-03","conditions":"COVID-19","enrollment":241},{"nctId":"NCT04866069","phase":"PHASE1","title":"Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults","status":"TERMINATED","sponsor":"Osman ERGANIS, PhD, Prof","startDate":"2021-04-25","conditions":"Covid19","enrollment":50},{"nctId":"NCT02814708","phase":"PHASE2","title":"Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Biomedizinische Forschungs gmbH","startDate":"2016-05","conditions":"Toxic Shock Syndrome","enrollment":140},{"nctId":"NCT01030874","phase":"NA","title":"Orthostatic Hypotension Treatment on Rehab Unit","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2011-10","conditions":"Orthostatic Hypotension, Falls","enrollment":356},{"nctId":"NCT02669121","phase":"PHASE2","title":"Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-06-14","conditions":"Healthy Volunteers","enrollment":4748},{"nctId":"NCT00481767","phase":"PHASE3","title":"Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-01","conditions":"Human Papillomavirus (HPV) Infection","enrollment":676},{"nctId":"NCT00586339","phase":"PHASE2","title":"Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01-17","conditions":"Infections, Papillomavirus","enrollment":150},{"nctId":"NCT00294047","phase":"PHASE3","title":"Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-16","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":5752},{"nctId":"NCT03174886","phase":"PHASE1","title":"A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia","status":"UNKNOWN","sponsor":"Axon Neuroscience SE","startDate":"2017-07-31","conditions":"Primary Progressive Nonfluent Aphasia","enrollment":33},{"nctId":"NCT01190176","phase":"PHASE3","title":"Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-09-12","conditions":"Infections, Papillomavirus","enrollment":34},{"nctId":"NCT01168401","phase":"PHASE1","title":"Bivalent Norovirus Vaccine Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-09-03","conditions":"Gastroenteritis","enrollment":102},{"nctId":"NCT02280447","phase":"PHASE1, PHASE2","title":"3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, as Booster Vaccination to Adolescents","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2014-11-13","conditions":"Immunization, Booster","enrollment":240},{"nctId":"NCT02787109","phase":"PHASE1","title":"Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2016-07","conditions":"Chlamydia Trachomatis","enrollment":35},{"nctId":"NCT02038907","phase":"PHASE2","title":"Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-03-28","conditions":"Healthy Volunteers, Norovirus, Prevention","enrollment":420},{"nctId":"NCT02971670","phase":"PHASE1","title":"Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial","status":"COMPLETED","sponsor":"Biomedizinische Forschungs gmbH","startDate":"2015-10","conditions":"Toxic-Shock Syndrome, Sepsis","enrollment":23},{"nctId":"NCT02340338","phase":"PHASE1","title":"rTSST-1 Variant Vaccine Phase 1 First-in-man Trail","status":"COMPLETED","sponsor":"Biomedizinische Forschungs gmbH","startDate":"2014-07","conditions":"Toxic Shock Syndrome, Vaccination; Sepsis","enrollment":46},{"nctId":"NCT00693966","phase":"PHASE2","title":"Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-10","conditions":"Infections, Papillomavirus","enrollment":210},{"nctId":"NCT00693615","phase":"PHASE2","title":"Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-10","conditions":"Infections, Papillomavirus","enrollment":60},{"nctId":"NCT00689741","phase":"PHASE2","title":"Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-01","conditions":"Infections, Papillomavirus","enrollment":1113},{"nctId":"NCT02271009","phase":"PHASE2","title":"Compare Dose Regimens of AllerT, in Adults With Allergic Rhino-Conjunctivitis to Birch Pollen Studied in EEC","status":"COMPLETED","sponsor":"Anergis","startDate":"2014-10","conditions":"Allergic Rhino-Conjunctivitis","enrollment":213},{"nctId":"NCT00717834","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of a Ross River Virus (RRV) Vaccine","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-06","conditions":"Ross River Virus Disease (RRVD)","enrollment":400},{"nctId":"NCT01296386","phase":"PHASE1","title":"An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-12","conditions":"Clostridium Difficile Infection","enrollment":82},{"nctId":"NCT00666341","phase":"PHASE2","title":"Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2007-09","conditions":"Type I-Allergy","enrollment":50},{"nctId":"NCT01111968","phase":"PHASE1","title":"Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2010-01","conditions":"Influenza","enrollment":266},{"nctId":"NCT00778388","phase":"PHASE1","title":"Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2008-09","conditions":"Healthy","enrollment":157},{"nctId":"NCT01605786","phase":"PHASE1, PHASE2","title":"Trial for Malaria Vaccine Candidate, PfPEBS (P. Falciparum Pre-Erythrocytic and Blood Stage)","status":"UNKNOWN","sponsor":"Vac4All","startDate":"2012-05","conditions":"Malaria","enrollment":36}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DEEP VEIN THROMBOSIS"},{"count":1,"reaction":"ABDOMINAL DISCOMFORT"},{"count":1,"reaction":"ACCIDENTAL OVERDOSE"},{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"ADVERSE DRUG REACTION"},{"count":1,"reaction":"ALCOHOL POISONING"},{"count":1,"reaction":"ARTHRITIS"},{"count":1,"reaction":"BRONCHIECTASIS"},{"count":1,"reaction":"BURNS SECOND DEGREE"},{"count":1,"reaction":"BURSITIS"}],"_approvalHistory":[],"publicationCount":1257,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Al(OH)3","genericName":"Al(OH)3","companyName":"Janssen Vaccines & Prevention B.V.","companyId":"janssen-vaccines-prevention-b-v","modality":"Biologic","firstApprovalDate":"","aiSummary":"Aluminum hydroxide acts as an adjuvant that enhances immune response by promoting antigen presentation and activating innate immunity. Used for Vaccine adjuvant in phase 3 vaccine development by Janssen Vaccines & Prevention B.V..","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}